Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01718730 · ClinicalTrials.gov registry record

Cortical Excitability and Inhibition in MDD

A clinical trial, sponsored by Mayo Clinic.

Completed
Registry status
23
Enrollment target

NCT01718730: Completed study, sponsored by Mayo Clinic.

NCT01718730 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT01718730 has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
23 participants
Enrollment target

Study Summary

The purpose of this study is to learn if measures of brain activity are different in children and adolescents with depression who are in different stages of treatment. This is important because it may identify a biological marker for depression that could one day be used to identify depressed children who would benefit from certain treatments (medications for example), or to monitor how well treatments are working. Brain activity measures(known as cortical excitability and inhibition) will be collected by Transcranial Magnetic Stimulation (TMS). TMS is a noninvasive (no surgery or implants) brain stimulation technology which can make parts of the brain work without putting any wires or chemicals into the body. Measurements will take place over one 3-hour visit. This study does not provide any form of treatment. \*There is an optional portion of the study that uses a brain scan to gather measures of brain structure and brain chemicals. The brain scan is called magnetic resonance and spectroscopy (MRI/MRS). MRI/MRS uses magnetic fields to study the structure of the brain and brain chemicals. The PI will determine eligibility for the MRI/MRS portion of the study.

Primary Outcome

Motor Threshold (MT) is a single-pulse TMS measure of cortical excitability. A higher MT indicates decreased cortical excitability. Intracortical Facilitation (ICF) is a paired-pulse TMS measure of cortical excitability. A higher ICF indicates increased cortical excitability. Cortical Silent Period (CSP) is a single-pulse TMS measure of cortical inhibition. Longer CSP durations indicate greater cortical inhibition. Intracortical Inhibition (ICI) is a paired pulse TMS measure of cortical inhibiti

Interventions

  • DEVICE Transcranial Magnetic Stimulation (TMS)
  • DEVICE Magnetic Resonance Spectroscopy and Imaging

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2012-10
Est. Completion 2019-08
Mayo Clinic

2,844 total trials

What the finished NCT01718730 record still lists

NCT01718730 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 23 participants, a relatively small participant target.

The record links to 0 conditions, and to 2 interventions - of which Transcranial Magnetic Stimulation (TMS) is the first listed.

NCT01718730 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01718730 about?

NCT01718730 is a clinical study titled "Cortical Excitability and Inhibition in MDD". The purpose of this study is to learn if measures of brain activity are different in children and adolescents with depression who are in different stages of treatment. This is important because it may identify a biological marker for depression that could one day be used to identify depressed childr...

What is the current status of trial NCT01718730?

This trial is currently completed. The enrollment target is 23 participants. The study started on 2012-10. Estimated completion is 2019-08.

What interventions are being tested in trial NCT01718730?

The interventions under investigation include: Transcranial Magnetic Stimulation (TMS) (DEVICE), Magnetic Resonance Spectroscopy and Imaging (DEVICE).

Who is sponsoring clinical trial NCT01718730?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03616041 · 23 participants

    Capsule Endoscopy for Severe Hematochezia

  • NCT04348747 · 23 participants · Phase 2

    Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

  • NCT04587687 · 23 participants · Phase 2

    Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

  • NCT04715022 · 23 participants · Phase 1

    Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01718730, the US trial registry maintained by the National Library of Medicine. NCT01718730 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.